{"analyses":[{"ciLowerLimit":"-0.0365","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.00873","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.2287","paramType":"Odds Ratio, log","paramValue":"-0.0139","statisticalMethod":"Regression, Logistic","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.6","value":"66.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"Clinical response is defined as MRD (minimal residual disease) measured by flow cytometry at day 22. The MRD at day 22 is classified as positive (with MRD) or negative (no detectable MRD). The relation between inhibition of DNA synthesis and MRD was performed by logistic regression. In the model, logit of probability of MRD positive was regressed on inhibition of DNA synthesis.","dispersionType":"Standard Error","groups":[{"description":"17 of the 232 eligible patients","id":"OG000","title":"Overall"}],"paramType":"MEAN","populationDescription":"Of 232 eligible patients, 49 had DNA synthesis rate performed prior to araC treatment. Of the 49 patients, 23 had no 24-hr samples and 3 did not have enough cells in 24-hr samples. 21 patients with both pre and post araC samples were included in the DNA inhibition study. 17 of the 21 patients had evaluable day 22 MRD.","reportingStatus":"POSTED","timeFrame":"Measurements were assessed in Induction I chemotherapy","title":"Relationship of Inhibition of DNA Synthesis and Clinical Response","type":"SECONDARY","unitOfMeasure":"Percent inhibition of DNA Synthesis"}